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Abstract: Fish protein represents one of the most widely consumed dietary protein sources by 
humans. The processing of material from the fishing industry generates substantial unexploited 
waste products, many of which possess high biological value. Protein hydrolysates, such as fish 
protein hydrolysates (FPH), containing predominantly di- and tripeptides, are more readily 
absorbed than free amino acids and intact protein. Furthermore, in animal models, FPH have been 
shown to possess numerous beneficial properties for cardiovascular, neurological, intestinal, renal, 
and immune health. Ageing is associated with the loss of skeletal muscle mass and function, as well 
as increased oxidative stress, compromised vascularisation, neurological derangements, and 
immunosenescence. Thus, there appears to be a potential application for FPH in older persons as a 
high-quality protein source that may also confer additional health benefits. Despite this, there 
remains a dearth of information concerning the impact of FPH on health outcomes in humans. The 
limited evidence from human interventional trials suggests that FPH may hold promise for 
supporting optimal body composition and maintaining gut integrity. FPH also provide a high-
quality source of dietary protein without negatively impacting on subjective appetite perceptions 
or regulatory hormones. Further studies are needed to assess the impact and utility of FPH on 
skeletal muscle health in older persons, ideally comparing FPH to ‘established’ protein sources or a 
non-bioactive, nitrogen-matched control. In particular, the effects of acute and chronic FPH 
consumption on post-exercise aminoacidaemia, skeletal muscle protein synthesis, and 
intramyocellular anabolic signalling in older adults are worthy of investigation. FPH may represent 
beneficial and sustainable alternative sources of high-quality protein to support skeletal muscle 
health and anabolism in ageing, without compromising appetite and subsequent energy intake. 
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1. Introduction 
Fish protein represents one of the most widely consumed dietary protein sources by humans, 
with global fish production peaking at around 171 million tonnes in 2016 [1]. In particular, the 
Scandinavian countries consume substantial amounts of fish, with Sweden and Norway consuming 
approximately 50 kg and 30 kg per capita, respectively, as of 1996 [2]. The processing of material from 
the fishing industry generates more than 60% of its by-products as rest, or waste, comprising skin, 
head, viscera, trimmings, liver, frames, bones and roes [3]. These by-products represent valuable, 
high-quality sources of protein and nutrients that are underused and/or unexploited [4–6]. Enzymatic 
hydrolysis is the preferred method of extracting these resources in the food and pharmaceutical 
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sectors, as other methods (i.e., chemical hydrolysis) can leave residual organic solvents or chemicals 
in the products [7]. Using this technique, protein biomass may be recovered from waste products that 
would otherwise be discarded [8], thus improving economic and environmental 
sufficiency/sustainability [9,10]. 
Protein hydrolysates providing mainly di- and tripeptides, the major protein fragments in fish 
protein hydrolysates (FPH), are absorbed more readily than free amino acids (AAs), and much more 
rapidly than intact protein [11,12]. The various FPH are breakdown products from the enzymatic 
conversion of fish proteins into smaller peptides, and normally contain 2–20 AAs [3]. In recent years, 
FPH have attracted considerable attention from food biotechnologists, given the abundance of raw 
material for the process, its high protein content, and desirable AA profile [3,12]. Importantly, this 
material is host to a plethora of bioactive peptides that may have practical applications in functional 
foods [3,5,8,10,13–15]. 
In vitro studies have suggested the beneficial properties of FPH-derived bioactive peptides, with 
potential applications for intestinal health [16,17], serum and liver cholesterol/lipid profile [18–21], 
fatty acid metabolism [22], postprandial glucose control [21], and hypertension [23]. There is also 
evidence in rodents that fish protein may increase plasma AA concentrations, their transport 
pathways [24], and associated fast-twitch muscle gene expression and mass [20]. Bioactive peptides 
released in the process of hydrolysation may also possess desirable immunomodulatory, anti-
inflammatory, antioxidant, and neuroprotective effects [25–28]. These beneficial properties have 
potential implications for older people, given that chronic inflammation [29], neurological 
derangements [30], compromised vascularisation [31], increased oxidative stress [32], alterations in 
the gut microbiome [33], impaired glucose homeostasis [34], and immunosenescence [35] are all 
linked with advancing age. 
In ageing, the progressive loss of muscle mass, strength, quality, and function, otherwise 
referred to as sarcopenia [36], is associated with a range of adverse health outcomes in humans. These 
include, but are not limited to, functional impairment [37,38], physical disability [39], decreased 
quality of life [40], an increased risk of falls [41], hospitalisation [42], and mortality [43]. The provision 
of dietary protein, particularly when consumed alongside resistance exercise, is recognised as an 
important strategy to manage and prevent sarcopenia in older persons [44–47]. Despite this, 31–50% 
of non-institutionalised older adults fail to meet the current Recommended Daily Allowance (RDA) 
of 0.8 g·kg−1·body mass−1·day−1 [48]. Moreover, several authors have advocated protein intakes in 
excess of 1.0 g·kg−1·body mass−1·day−1 for this population [49–52]. Although older people may be less 
responsive to low-dose AA servings, this ‘anabolic resistance’ may be overcome by optimising 
protein or essential amino acid (EAA) provision [49,53,54] and resistance exercise [46]. Somewhat 
paradoxically, it is well established that dietary protein has a dose-dependent satiating effect [55,56] 
that has implications for older people with dysregulated appetite perception and/or appetite 
hormones [57,58]. Therefore, efficacious protein formulations are required to address nutritional 
deficiencies in older people without compromising appetite and energy intake. FPH might represent 
a potential means of meeting this need. 
To date, one review has summarised the existing knowledge from animal and human clinical 
studies evaluating the effects of lean fish, fish proteins, and fish-derived peptides on metabolic health 
outcomes [5]. However, to our knowledge, the current evidence relating to FPH within the context of 
adult human health and ageing has not been outlined. Therefore, the purposes of this review were to 
(1) explore the present evidence on the impact of fish-derived protein formulations in adult human 
interventional studies, and (2) investigate the current and potential applications of these formulations 
on skeletal muscle health and function in ageing. 
2. Literature Search 
We searched the US National Library of Medicine (PubMed) and MEDLINE databases for 
human interventional studies, using ‘fish protein’, ‘marine protein’, ‘fish protein hydrolysate’, 
‘marine protein hydrolysate’ and ‘human’ as key terms. The Boolean operators “AND” and “OR” 
were used to combine search terms. Additional literature was obtained from ‘related articles’ searches 
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and by manually screening the reference lists of included studies. The literature search identified 349 
articles that were subsequently assessed for duplicate entries. Following screening for non-human 
studies, those that did not investigate FPH, and studies in paediatric populations, a total of 14 articles 
were included for review (Table 1). Only refereed articles published in English language peer-
reviewed journals from January 1980 until May 2020 were included. Studies published in abstract 
form or in the grey literature were not considered. 
3. Regulation of Human Physiological Function by Fish Protein Hydrolysates 
An overview of studies investigating the effects of FPH on human health is provided in Table 1. 
3.1. Vascular Function 
In a rodent model, FPH was shown to decrease systolic blood pressure and exert an inhibitory 
effect on angiotensin-I-converting enzyme [23]. In healthy humans, two studies explored the impact 
of FPH formulations on vascular function in the same laboratory, using similar designs [59,60]. Both 
investigations provided single FPH (hydrolysed from Nile tilapia) doses of either 5 g [59] or 20 g [60] 
and monitored vascular responsiveness at the brachial artery using flow-mediated dilation (FMD). 
Furthermore, both studies also measured the total antioxidant capacity (TAC) of each supplement 
using the Trolox equivalent antioxidant capacity assay. Oliveira et al. [60] found no beneficial effect 
of FPH over placebo (PLA) or whey protein hydrolysate (WPH) on FMD at baseline or during 120 
min post-supplementation. This was in spite of the fact that the TAC of the FPH supplement was 
greater than PLA (239.17 ± 3.91 versus 25.56 ± 0.00 mM Trolox Equivalent (TE)/20 g fresh weight; p ≤ 
0.001) and WPH (40.09 ± 13.32 mM TE/20 g fresh weight; p ≤ 0.001), respectively. The TAC of the WPH 
supplement was comparable to that of the PLA (p = 0.205). Consistent with Oliveira et al., Alvares et 
al. [59] found no beneficial effect of FPH over PLA on FMD values during 120 min post-
supplementation. In addition, microvascular function was measured using near-infrared 
spectroscopy (NIRS) to quantify tissue O2 saturation (StO2) in response to a vascular occlusion test at 
the brachial artery. No significant interaction effects were found between supplements for NIRS-
derived StO2. In agreement with Oliveira et al., the TAC of the FPH supplement was greater 
compared with PLA (569.4 ± 75 versus 0.0 mM TE/100 g; p < 0.05). Both studies recruited nine 
participants, with Alvares and colleagues acknowledging the low statistical power to detect 
differences between FPH and PLA (1 − β error = 0.08 − 0.37). 
Although the beneficial anti-hypertensive and antioxidant properties of FPH have been 
demonstrated in vitro [23,28,61] the existing evidence in humans suggests no benefit of FPH on 
arterial vascular responsiveness, despite its significantly greater TAC [59,60]. Indeed, the 
demonstration of bioactive properties in vitro does not necessarily infer that the same beneficial 
effects will be observed following human consumption [62]. It must also be recognised that the two 
human studies discussed here did not establish the in vivo postprandial redox state following 
supplementation, which would have been informative. The effects of FPH on vascular function and 
its mechanistic underpinnings in longitudinal studies and/or populations with elevated 
cardiovascular risk factors also remain to be elucidated. Such findings may be of benefit to older 
persons, as compromised vascular responsiveness has been posited to impede nutrient delivery (i.e., 
AAs) to skeletal muscle in this population [31], however the evidence for this is controversial. The 
nutraceutical and pharmaceutical modulation of skeletal muscle blood flow has not been shown to 
enhance muscle protein synthesis (MPS) in the presence of dietary protein or EAAs in younger and 
older adults [63–66]. Contrastingly, others have observed a positive effect of increased skeletal muscle 
perfusion and AA provision on MPS in older adults [67]. The purported beneficial impact of FPH on 
skeletal muscle blood flow, nutrient delivery, and MPS therefore remains to be established in 
humans. 
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Table 1. Intervention trials exploring the effects of fish-derived protein hydrolysates on health, exercise performance, and ageing in healthy humans. 
Reference Participants Research Design FPH Source Species Dosage Exercise Protocol Main Outcomes Key Findings 
Alvares et al. [59] 
Healthy adults (6 
males, 3 females; 








5 g FPH or PLA 
(sucralose) dissolved 
in 100 mL water 
N/A 
Primary outcomes: Flow-mediated 
dilation (FMD), tissue oxygen 
saturation (StO2)  
Secondary outcome: total antioxidant 
capacity (TAC) of each beverage 
FMD and StO2 parameters did 
not significantly change 
between FPH and PLA 
supplementation. TAC was 
significantly greater in the 
FPH supplement compared 
with the PLA. 
 
Cordeiro et al. [68] 
Physically active 
subjects  
(6 males, 3 females; 








mass−1 WPH, FPH or 
PLA immediately  
following RE 
3 sets × 10–12 RM 
leg press and leg 
extension 
Primary outcomes: Plasma TAAs, EAAs, 
BCAAs, leucine (0, 30, 60, 90, 120, 180 
min post-supplement) 
Rapid and pronounced 
aminoacidaemia was observed 
following FPH and WPH, with 
no significant differences 
between protein sources at any 
time point. 
 
Dale et al. [69] 
Healthy, active 
individuals  
(15 males, 26 
females;  






20 mg FPH or casein 





Primary outcomes: Serum glucose and 
insulin at 20 min intervals from 0 to 180 
min postprandial  
Secondary outcomes: Plasma GLP-1 at the 
same time points 
Postprandial serum insulin 
secretion was significantly 
lower following FPH, with no 
difference observed between 
FPH and control for serum 
glucose or plasma GLP-1. 
Dale et al. [70] 
Healthy 
individuals  
(15 males, 26 







20 mg FPH or casein 





Primary outcomes: Plasma acylated 
ghrelin at 0, 20, 40, 80, 180 min 
postprandial 
Secondary outcomes: Subjective appetite 
sensations at the same time points 
No effect of single-dose FPH 
on plasma acylated ghrelin, 
subjective satiety,  
or fullness sensations. 
Dale et al. [71] 
Irritable bowel 
syndrome (IBS) 
patients: FPH (n = 
13, age 42.7 ± 11.9 
years) or PLA (n = 









2.5 g FPH or PLA 
(maltodextrin) 
consumed daily for 
six weeks 
N/A 
Primary outcomes: IBS-SSS and QoL 
scores 
Secondary outcomes: Serum pro-
inflammatory cytokines and gut 
integrity markers, faecal SCFAs  
and calprotectin  
Total IBS-SSS scores reduced 
in both groups and did not 
differ at the end of the six 
weeks. No significant changes 
in serum pro-inflammatory 
cytokines, gut integrity 
markers or faecal measures. 
 





group: n = 12, age 
84 ± 8 years; 
control group:  









5.2 g FPH or PLA 
daily for six weeks 
N/A 
Primary outcome: Feasibility of FPH 
intervention in older nursing home 
residents (participant compliance).  
Secondary outcomes: Serum markers of 
glucose metabolism  
and inflammation (MCP-1, CRP) 
FPH intervention was feasible 
(completion rate = 88%). No 
significant between-group 
differences in baseline 
parameters. Serum MCP-1 was 
reduced and CRP increased 
from baseline to endpoint in 
the intervention group 
compared with the control 
group. Glucose, insulin, and 
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fructosamine were unaffected 
by the intervention. 
 
Jensen et al. [73] 
Healthy older 
adults  
(13 male, 18 








10, 20, 30, or 40 
mg·kg−1·body weight 
daily for one week 
with washout 
periods (one week)  
in between 
N/A 
Primary outcomes: Serum glucose and 
insulin at 20 min intervals for 2 h 
following FPH consumption and 
standardised breakfast on day 7  
of each cycle.  
Secondary outcomes: Plasma GLP-1 at the 
same time points 
No differences in estimated 
maximum value of insulin, 
glucose, or GLP-1 were found 
when comparing the lowest 
dose to higher doses. No 
significant differences in total 
AUC for any variable 
irrespective of dose. 
Marchbank et al. [74] 
Healthy volunteers 
(age 25–40 years; 5 






1 g FPH or placebo 
capsule three times 
daily for seven days 
followed by a two-
week washout 
period, then the 
corresponding arm. 
Indomethacin (50 mg 
three times daily) 
was added for the 
final five days. 
 
N/A 
Primary outcomes: Gut permeability 
measured using 5 h urinary 
lactulose:rhamnose ratios.  
Secondary outcome: Dyspepsia incidence 
Gut permeability increased 
approximately five-fold in 
placebo and indomethacin, but 
this effect was mitigated in the 
FPH arm. Dyspepsia was 
present in 50% of participants 
in the placebo arm but 0% in  
the FPH arm. 
Mjøs et al. [75] 
Healthy, trained, 
male cyclists (age 













a cycling session, 
then 4 h recovery 
before an identical  
cycling session 
20 min moderate 
intensity cycling at 
60% VO2max; 90% 
VO2max for 5 min, 
then TTE at 95% 
VO2max 
Primary outcome: TTE.  
Secondary outcomes: HR, RER, blood 
lactate, and glucose 
No significant difference 
between supplementations 
measured by TTE, HR, RER, 
blood glucose, or lactate. 
Nobile et al. [76] 
Healthy, slightly 
overweight  
(25 kg/m2 ≤ BMI ≤ 
30 kg/m2) male 
(25%) and female 











Either 1.4 g FPH, 2.8 
g FPH, or whey 
protein isolate (PLA) 
daily for 90 
consecutive days 
N/A 
Primary outcomes: Body composition 
(weight, fat mass, extracellular water, 
circumference of the waist, hips,  
and thighs) 
Secondary outcomes: Fasting plasma 
concentrations of total CCK and GLP-1 
Treated subjects had improved 
body composition after 90 
days. Measured end points did 
not differ significantly 
between 1.4 g and 2.8 g FPH. 
Increased fasting 
concentrations of CCK and 
GLP-1 were observed after 90 
days in all conditions. 
 
Oliveira et al. [60] 
Healthy young (6 
males, 3 females; 









20 g single dose of 
FPH, WPH dissolved 
in 100 mL water or 5 
g PLA (sucralose; six 
capsules) taken with 
100 mL water 
N/A 
Primary outcome: FMD at 10, 30, 60, and 
120 min postprandial. Secondary 
outcome: Total antioxidant capacity 
(TAC) of each condition. 
Endothelium-dependent 
dilation increased at 30 min 
following WPH but not FPH. 
TAC was greater in the FPH 
compared with the WPH  
and PLA. 
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Siegler et al. [77] 
Healthy (median 
(IQR): age 23 (6) 
years), aerobically 
trained males 
(mean ± SD: 






180 mL of the 
following beverages 
every 15 min during 
exercise (CHO only: 
67 g·h−1 maltodextrin; 
CHO-PRO: 53.1 g·h−1 
maltodextrin and 
13.6 g·h−1 WPC; 
CHO-PRO-PEP: 53.1 
g·h−1 maltodextrin, 
13.6 g·h−1 WPC, and 
2.4 g·h−1 FPH) 
90 min bout of 
cycling at 50% 
Wmax followed by a 
5-km time trial 
Primary outcome: 5-km TT time to 
completion, power output.  
Secondary outcomes: RER, HR 
Mean 5-km TT time to 
completion and power output 
did not differ between trials. 
RER in CHO-PRO was higher 
than CHO and CHO-PRO-
PEP. 
Vegge, Rønnestad  
and Ellefsen [78] 
Well-trained male 
cyclists (age 22 ± 2 








Either a CHO 
beverage containing 
8.3% maltodextrin 
(60 g·h−1), PROCHO 
(maltodextrin and 
2.1% intact whey 
protein, 12.4 g·h−1), or 
NpPROCHO 
(maltodextrin and 




(120 min) at 50% 
Wmax followed  
by 5 min mean-
power test 
Primary outcome: 5-min  
mean-power performance.  
Secondary outcomes: HR, VO2, RER, RPE, 
blood glucose and lactate,  
blood urea nitrogen 
5-min mean-power did not 
differ between beverages. 
There were no differences 
between beverages for HR, 
RER, VO2, glucose, lactate, or 
RPE. Blood urea nitrogen 
significantly increased from 
baseline to 120 min in 
NpPROCHO  
and PROCHO only. 
Zaïr et al. [79] 
Healthy, 
overweight  
(BMI: 25–30 kg/m2) 







1 g FPH or placebo 
(microcrystalline 
cellulose) twice daily 
for two weeks, 
followed by a two-
week washout 
period. Testing 
sessions lasted 420 
min, with products 
consumed at 0 min 
and 240 min, 
followed by an ad 
libitum lunch  
at 270 min 
N/A 
Primary outcome: Subjective  
appetite sensations.  
Secondary outcomes: Plasma glucose, 
insulin, CCK, and GLP-1. Ad libitum 
energy intake 
No differences in hunger AUC 
between FPH and placebo. 
Lower plasma glucose at 270 
min in FPH compared with 
PLA. No differences in plasma 
insulin, CCK and GLP-1 or ad 
libitum energy intake 
Abbreviations: AUC, area under the curve; BCAA, branched-chain amino acid; BMI, body mass index; CCK, cholecystokinin; CHO, carbohydrate; CRP, C-reactive 
protein; EAA, essential amino acid; FMD, flow-mediated dilation; FPH/PEP, fish protein hydrolysate; GLP-1, glucagon-like peptide 1; HR, heart rate; IBS-SSS, 
Irritable Bowel Syndrome Severity Scoring System; IQR, interquartile range; MCP-1, monocyte chemoattractant protein 1; N/A, not applicable; PLA, placebo; PRO, 
protein; QoL, quality of life; RER, respiratory exchange ratio; RPE, rating of perceived exertion; SCFA, short-chain fatty acid; SD, standard deviation; StO2, skeletal 
muscle oxygen saturation; TAA, total amino acid; TAC, total antioxidant capacity; TT, time trial; TTE, time to exhaustion; WPC, whey protein concentrate; WPH, 
whey protein hydrolysate; VO2, volume of oxygen; VO2max, maximal oxygen uptake. 
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3.2. Appetite Regulation 
Four studies were found that investigated the impact of FPH on subjective appetite ratings 
and/or circulating appetite hormones in healthy adults [69,70,76,79]. The earliest investigation by Zaïr 
et al. [79] found no significant differences between a blue whiting-derived FPH and PLA on area 
under the curve (AUC) subjective hunger perceptions or biomarkers of appetite/satiety including 
plasma cholecystokinin (CCK) and glucagon-like peptide 1 (GLP-1). Similarly, no difference in ad 
libitum energy intake was found between conditions. Nobile et al. [76] found that total fasting plasma 
CCK and GLP-1 concentrations were increased following 90 days of blue whiting-derived FPH 
supplementation (1.4 g versus 2.8 g per day) and to a greater extent compared with PLA. Both CCK 
and GLP-1 are insulinotropic peptides known to stimulate satiety [80,81]; however, complementary 
subjective ratings of appetite (i.e., visual analogue scales [82]) in this study were not measured. More 
recent work by Dale et al. [70] found no differences in GLP-1 concentrations after consuming 20 
mg·kg−1·body mass-1 of either an FPH derived from Atlantic cod or a casein control. In a similar study 
using the same cohort, postprandial and total AUC concentrations of acylated ghrelin, a peripheral 
hormone with orexigenic properties, did not differ between FPH and control [70]. Similarly, no 
between-group differences were found for subjective satiety scores and feelings of fullness. Lastly, 
Jensen and colleagues [73] conducted a dose-ranging crossover study (daily supplementation for one 
week) of a cod-derived FPH in healthy older volunteers aged 60–78 years. No differences in the 
estimated maximum value or AUC of serum GLP-1 were observed when comparing the lowest dose 
of FPH (10 mg·kg−1·body mass−1) against the higher doses (20, 30, or 40 mg·kg−1·body mass−1), 
suggesting the FPH was ineffective. The lack of a placebo control further complicates the 
interpretation and significance of these findings. 
Taken together, these findings suggest that—irrespective of source species—the consumption of 
FPH does not detrimentally impact appetite regulation or subsequent ad libitum energy intake in 
healthy young and middle-aged participants. However, to date, no studies have been undertaken on 
the role of FPH in appetite regulation, its potential impact on protein intake, and subsequent effects 
on MPS and skeletal muscle health in older adults. 
3.3. Glycaemic Control 
Four studies incorporated measures of blood glucose and/or insulin concentrations in response 
to FPH consumption. Zaïr et al. [79] explored the impact of two separate doses of FPH compared 
with PLA over the course of a 420 min acute trial in overweight but otherwise healthy, 
normoglycaemic women. Trials were preceded by two weeks of supplementation with two daily 
doses of 1 g FPH or PLA. Plasma glucose was significantly lower at 270 min post-consumption of the 
first 333 mg dose (i.e., 30 min following the consumption of the second identical dose) in the FPH 
condition compared with PLA (4.71 ± 0.42 versus 4.93 ± 0.51 mmol·L−1; p < 0.05). Interestingly, there 
were no significant differences in plasma insulin concentrations between groups at any measurement 
point. Although the omega-3 polyunsaturated fatty acid content of the supplement was not specified, 
eicosapentaenoic acid (EPA) has been shown to mediate skeletal muscle glucose uptake in murine 
C2C12 cells, through AMP-activated protein kinase (AMPK) signalling and glucose transporter 4 
(GLUT4) translocation [83]. In addition, omega-3 index (i.e., red blood cell concentrations of EPA and 
docosahexaenoic acid (DHA)) was positively associated with insulin sensitivity (r = 0.23; p = 0.025) in 
a study of 47 overweight, middle-aged males [84]. 
In contrast with Zaïr et al., Dale et al. [69] found no differences in serum glucose between FPH 
and a casein control for either time series, peak concentration, or postprandial AUC. In a mixed-
model linear regression analysis, serum insulin concentration was significantly lower after FPH 
consumption compared with the control (mean difference between geometric means (95% confidence 
interval (CI)): 1.067 (1.01, 1.13) mIU·L−1; p = 0.032). However, no significant differences in peak 
concentration or AUC values were reported. The reduced insulin concentration in the absence of 
changes in blood glucose in this study run counter to the findings of Zaïr et al., potentially due to the 
choice of FPH (blue whiting versus cod) and/or the use of a two-week supplementation period by 
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Zaïr et al. However, without more detailed information on the supplement composition in Zaïr et al., 
it is difficult to substantiate these notions. Taken together, these findings suggest that FPH may have 
a role in the regulation of glucose uptake and insulin sensitivity in young adults. 
In older volunteers, Jensen et al. [73] performed a dose-ranging crossover study that found no 
difference in the estimated maximum value of serum glucose or insulin when comparing the lowest 
dose of FPH against the higher doses. Furthermore, no differences were found in AUC for these 
measures when comparing the lowest dose with the higher doses. However, the lack of a dose–
response is difficult to interpret without the context of a placebo control. It should also be noted that 
the doses of FPH used in this study were considerably lower (40 mg·kg−1·body mass−1 at the upper 
limit) when compared with other studies of FPH and/or WPH [68,85]. Although serum glucose and 
insulin appeared to decline with increasing amounts of FPH, these changes did not attain statistical 
significance. These data suggest that higher doses of FPH may be beneficial for glucose control, but 
this requires further substantiation. 
In a feasibility study of older (>80 years) nursing home residents, Drotningsvik et al. [72] 
investigated the impact of six weeks daily supplementation with 5.2 g of blue whiting-derived FPH 
versus a placebo on serum markers of glucose metabolism (i.e., fasting glucose, insulin, and 
fructosamine). Participant completion was high (88%), and exceeded that reported in previous 
supplementation studies in older persons [86,87]. Although the study was feasible and safe, with a 
low dropout (n = 3), recruitment was difficult given the target population. In addition, the 
intervention did not affect fasting serum glucose, insulin, and fructosamine. 
Collectively, these findings suggest that in young and older volunteers, there is some evidence 
for a benefit of FPH supplementation on glycaemic control, but much further work is required in this 
area. The inconsistent findings from the aforementioned studies mirror the broader literature, 
particularly with regard to moderate (i.e., 2–3 g) and high dose (>5 g) omega-3 polyunsaturated fatty 
acid supplementation [88]. Although the administration of FPH appears to be safe and does not pose 
deleterious consequences for glucose homeostasis, more high-quality randomised controlled trials 
are necessary to reliably determine the impact of FPH on insulin sensitivity and glycaemic control. 
Such investigations may measure postprandial glucose and insulin concentrations following an oral 
glucose tolerance test, or the gold-standard hyperinsulinaemic–euglycaemic clamp technique [89]. 
The findings from these trials may be of particular importance for older persons, given that glycaemic 
control may be impaired in this population due to losses in skeletal muscle mass and function that 
predispose individuals to reduced skeletal muscle insulin sensitivity [34,90]. 
3.4. Body Composition 
Nobile et al. [76] found that 90 days of FPH supplementation (1.4 g or 2.8 g) combined with a 
daily caloric deficit of 300 kcal decreased body weight, body mass index, dual-energy X-ray 
absorptiometry (DXA)-derived fat mass, and waist, hip, and thigh circumference to a similar extent 
compared with a whey protein isolate control. No significant changes were observed in extracellular 
water, and there were no significant differences between FPH doses or the whey protein isolate 
control for all measured endpoints. Measures of lean mass, fat-free mass, and bone mineral content 
by DXA were not reported; hence, the contributions of these tissues to the overall body weight 
reductions, as per the three-compartment model [91], are unclear. From these data, it is inconclusive 
that the FPH had any impact on body composition as the observed changes are likely attributable to 
the caloric deficit achieved through alimentary diaries. 
3.5. Plasma Aminoacidaemia 
The availability of AAs is crucial for the regulation of MPS [92], with rapid aminoacidaemia 
serving to enhance skeletal muscle anabolism and MPS following resistance exercise [93]. Dietary 
protein, particularly EAAs, drives anabolism and MPS through mammalian target of rapamycin 
complex 1 (mTORC1) signalling [44,94,95]. Among the EAAs, leucine is well known for its unique 
ability to stimulate mRNA translation via mTOR signalling and that of its downstream effectors 
ribosomal protein S6 kinase (p70S6K), eukaryotic translation initiation factor 4E-binding protein 1 
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(4E-BP1) and ribosomal protein S6 kinase (rpS6) [94,96]. Hence, the leucine and EAA content of a 
given protein source are key considerations for skeletal MPS. 
Of the 14 studies included in this review, the AA composition of each FPH (if available) is 
provided in Table 2. There was considerable variation in the AA profile of each FPH, both within and 
between species, as well as among the WPH comparators. 
Table 2. Essential amino acid composition of various FPH alongside their comparative WPH from 
among the reviewed studies. Approach adapted from van Vliet et al. [97]. 
Author(s) Source Species Essential Amino Acids, mg/g Leucine, mg/g 
FPH    
Alvares et al. [59], Oliveira et al. [60] Nile tilapia 772.01 ± 107.17 75.07 ± 14.24 
Cordeiro et al. [68] Nile tilapia 347.40 ± 48.23 33.78 ± 6.41 
Dale et al. [69–71],  
Jensen et al. [73] 
Atlantic cod 294.3 60.3 
Drotningsvik et al. [72] * Blue whiting 375.3 72.7 
WPH    
Cordeiro et al. [68] Not specified 458.60 ± 42.20 49.43 ± 5.74 
Oliveira et al. [60] Not specified 1019.05 ± 93.79 109.85 ± 12.76 
Notes: FPH, fish protein hydrolysate; WPH, whey protein hydrolysate. The asterisk indicates that 
EAA content was calculated in the absence of exact mg/g measures using information provided in the 
article. 
One study explored the impact of a Nile tilapia-derived FPH compared with WPH on post-
exercise aminoacidaemia in healthy young individuals [68]. Immediately following a resistance 
exercise bout, 0.25 g·kg−1·body mass−1 of oral FPH, WPH, or PLA were consumed. Significant 
increases in total AAs, EAAs, branched-chain amino acids, and leucine were observed in the FPH 
trial at 30 and 60 min postprandial compared with PLA. There were no significant differences 
between FPH and WPH at any time point or for AUC concentrations. This is surprising, given the 
reduced leucine and EAA content compared with WPH. The effects of FPH formulations from other 
species and/or those providing greater amounts of leucine on plasma aminoacidaemia and skeletal 
muscle anabolism remain to be determined. These findings indicate that this particular FPH 
formulation induced comparable plasma aminoacidaemia to a WPH formulation and thus may 
represent a viable alternative source of high-quality dietary protein for supporting the maintenance 
of skeletal muscle mass. 
3.6. Intestinal Health 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used by older persons, with 7.3% 
of all individuals over 65 years of age filling at least one prescription for reimbursed NSAIDs during 
a 12-month period [98]. An increase in gastrointestinal (GI) tract permeability may result in the 
decreased absorption of nutrients, particularly AAs, that play a crucial role in skeletal muscle health 
[92,99]. 
The impact of a pacific whiting-derived FPH compared with PLA on gut permeability was 
investigated by Marchbank et al. [74]. Participants consumed 1 g capsules of FPH or PLA three times 
daily for a total of seven days. After two days of supplementation, the NSAID indomethacin, a 
substance known to negatively affect the integrity of the small intestine, was added (50 mg three 
times daily for five days). Changes in gut permeability were measured using 5 h urinary 
lactulose/rhamnose (L/R) ratios. In the absence of indomethacin, FPH did not affect gut permeability. 
In response to indomethacin during the PLA arm, gut permeability increased by approximately five-
fold. However, in the FPH arm, the increase in gut permeability was truncated, suggesting a 
protective effect against indomethacin-induced injury [74]. Dyspepsia was present in 50% of 
participants in the PLA arm, but none in the FPH arm. Although ageing itself can increase the risk of 
bleeding in the GI tract, GI ulceration and bleeding can be exacerbated in older persons through 
NSAID use [100]. This process is driven by the NSAID-induced inhibition of prostaglandin synthesis, 
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causing a weakening of the mucosal barrier that protects the GI tract [100]. These findings indicate 
that short-term supplementation with a pacific whiting-derived FPH may be beneficial for preventing 
NSAID-induced intestinal injury, but the evidence for chronic supplementation is limited at present. 
3.7. Inflammation 
Two studies investigated markers of inflammation in response to FPH consumption. In the 
chronic study by Drotningsvik et al. [72] in nursing home residents, serum concentrations of the 
inflammatory marker monocyte chemoattractant protein-1 (MCP-1) were significantly reduced 
(mean difference (95% CI): −80 (−146, −13) pg·mL−1; p = 0.0064) after six weeks of supplementation in 
the FPH group, whereas C-reactive protein (CRP) significantly increased compared with the control 
group (0.77 (−6.83, 8.37) mg·L−1; p = 0.040). 
Dale et al. [71] examined the effects of daily supplementation with cod-derived FPH (2.5 g) 
versus a placebo for six months on serum concentrations of gut integrity markers (intestinal fatty acid 
binding protein (iFABP), lipopolysaccharide-binding protein (LBP), and zonulin) and pro-
inflammatory cytokines (tumor necrosis factor alpha, interferon gamma, interleukin 4, 6, 8, and 10) 
in irritable bowel syndrome (IBS) patients. Although there was no significant change in these markers 
in either group, the impact of larger doses of FPH and/or FPH derived from other species on these 
aspects remains to be established. 
Hence, given these inconclusive findings, further investigation is necessary to explore the impact 
of FPH on inflammatory markers and the associated impact on skeletal muscle health and function 
in older adults. 
3.8. Skeletal Muscle Function and Exercise Performance 
Four studies were found that investigated the effects of FPH on exercise performance and 
physical function in trained individuals and older nursing home residents, respectively. 
In moderate to well-trained cyclists, Vegge, Rønnestad, and Ellefsen [78] assessed 5-min mean-
power performance following 120 min of steady-state cycling at 50% maximal aerobic power after 
the consumption of three beverages: carbohydrate alone (CHO; 8.3% maltodextrin; 60 g·h−1), 
PROCHO (CHO plus 2.1% intact whey protein; 15.3 g·h−1), and NpPROCHO (PROCHO plus 0.4% 
NutripeptinTM (Np); 2.7 g·h−1). No differences in 5-min mean-power performance were observed 
between the three beverages. However, an ergogenic effect on this measure was noted in the six lesser 
performing participants compared with the six better performing participants in NpPROCHO 
relative to ingestion of CHO alone. This preliminary evidence suggests a potential ergogenic benefit 
when supplementing with FPH in athletes at a lower level of performance. 
In healthy aerobically trained males, 5-km time trial (TT) time to completion and power output 
did not differ when 2.4 g of FPH were added to a CHO-PRO beverage (53.1 g·h−1 maltodextrin and 
13.6 g·h−1 whey protein concentrate) versus CHO-PRO and CHO alone [77]. Respiratory exchange 
ratio (RER) during a steady-state phase (50% of maximal power output for 90 min) was higher in 
CHO-PRO compared with CHO alone and CHO-PRO supplemented with FPH, suggesting greater 
fat oxidation in the latter two beverages. Therefore, although the FPH condition appeared to influence 
metabolism during the steady-state phase, these effects did not translate into a beneficial performance 
outcome. 
Contrastingly, Mjøs et al. [75] explored the impact of FPH on short-term recovery between 
cycling bouts in healthy middle-aged cyclists. They found no difference in time to exhaustion, heart 
rate, RER, blood lactate, and glucose following the addition of FPH (20 mg) to a whey protein and 
carbohydrate formulation compared with an isoenergetic, isonitrogenous FPH-free supplement. The 
small dose of FPH may not have been sufficient to exert a substantial effect, and/or it may have been 
confounded by the simultaneous provision of whey protein and carbohydrate (12% and 66% of the 
energy composition from each beverage, respectively). Moreover, the doses of FPH used in all three 
exercise performance studies were small, and the influence of larger doses, acutely or chronically, on 
fat oxidation rates in cycling are not yet established. At present, these findings appear to reinforce 
the notion that for highly trained athletes, carbohydrate availability is the rate-limiting factor for 
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performance in events lasting up to 3 h [101]. Therefore, the performance data presented here do not 
substantiate the use of FPH in this context. 
Lastly, in the feasibility study of older (>80 years) nursing home residents by Drotningsvik et al. 
[72], body weight and handgrip strength were similar between groups at baseline and did not 
significantly change by the endpoint (data not presented). The amount of protein provided here (5.2 
g per day) and the duration of supplementation may have been insufficient to attain a beneficial effect 
in this population. For example, Björkman et al. [102] observed a 2.1% increase in body weight after 
six months of supplementation with whey protein (20 g·day−1) in nursing home residents, whereas 
body weight declined by 1.9% in a control group. Although handgrip strength responses were similar 
between groups, individuals in the whey protein group required less physical assistance after the 
trial period. It is also important to note the synergistic role of resistance exercise alongside dietary 
protein for driving improvements in skeletal muscle mass and strength [45,46]. Frail older adults 
have been shown to respond to 24 weeks of dietary protein supplementation (30 g·day−1) when 
engaging in a progressive resistance exercise programme [103]. Lean mass increased by 
approximately 1.3 kg in the protein group and did not change in a placebo group, whereas handgrip 
strength increased in both groups. These findings highlight the role of protein intake in supporting 
skeletal muscle mass gains in frail older adults whilst underlining the integral value of resistance 
exercise training for strength and functional performance. The utility of FPH supplementation when 
allied to a programme of resistance exercise training remains to be explored in older and/or frail 
populations. 
Taken together, these findings do not yet support the use of FPH in the context of the 
performance and functional outcomes measured in the above studies. 
4. A Potential Role for FPH in Maintaining Skeletal Muscle Health and Preventing Age-Associated 
Sarcopenia 
To date, there is a dearth of human studies investigating the bioactivity of FPH, and as such, 
there is great opportunity for future research to build on preliminary work in this area. Despite the 
limited evidence available at this time, the findings of this review have highlighted potential 
beneficial outcomes related to skeletal muscle health and mass through supplementation with FPH. 
At present, only one registered clinical trial is investigating the utility of FPH on measures of skeletal 
muscle health and function in older adults [104], thus further illustrating this area of opportunity. 
Dietary protein is recognised as a key nutrient for older persons, particularly in relation to 
skeletal muscle mass, function, and health [99,105]. Numerous authors have advised intakes in excess 
of the present RDA for this population [49,51,52,105,106]. These recommendations are supported in 
part by the reduced anabolic sensitivity of skeletal muscle in older adults that may be brought about 
by any of a number of factors: reduced physical activity levels [107], increased splanchnic AA 
retention (particularly leucine) leading to attenuated aminoacidaemia [108], low-grade inflammation 
[109,110], reduced skeletal muscle amino acid transporter expression [111,112], and blunted anabolic 
signalling [51,113]. However, these dietary protein recommendations may pose a challenge for older 
individuals with compromised appetite and/or dysregulated appetite hormones [57], given that 
dietary proteins have a dose-dependent satiating effect [52,55,56,114]. The absence of deleterious 
effects on subjective appetite perceptions and regulatory hormones following FPH consumption in 
young and middle-aged participants [69,70,76,79] is promising but requires verification in older 
persons. To date, no study has explored the effects of FPH on appetite regulation in older individuals. 
Irrespective of the daily protein requirement, the widespread use of NSAIDs in older persons 
and the increased susceptibility to GI tract ulceration and bleeding may negatively affect nutrient 
(and particularly AA) delivery, thus posing consequences for skeletal muscle health. The protective 
role of FPH on NSAID-induced injury in younger volunteers was demonstrated by Marchbank et al. 
[74]; however, this effect remains to be corroborated in older populations. FPH may hold promise as 
a useful prophylactic against NSAID-induced GI tract damage in older adults whilst also providing 
a high-quality source of dietary protein. 
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The compromised vascularisation associated with advancing age is proposed to hinder nutrient 
delivery to skeletal muscle [31], yet pharmaceutical and nutraceutical modulation of skeletal muscle 
blood flow has not reliably been shown to enhance MPS in the presence of dietary protein and EAAs 
in younger and older adults [63–66]. Despite promising findings in rodent models, there were no 
beneficial effects on vascular function in the two human studies reviewed here. This may have been 
a consequence of the low dose provided, or the small sample sizes recruited. To date, no study has 
investigated the effects of FPH on arterial vascular responsiveness in older volunteers. The greater 
TAC of the FPH beverage over PLA and WPH in both studies may influence vascular function and 
muscle health in older adults and warrants further exploration. 
The comparable post-exercise aminoacidaemia observed in young individuals following FPH 
and WPH ingestion [68] indicates a potential role for FPH as an alternative and sustainable dietary 
protein source in ageing. Such FPH formulations may represent useful adjuncts to suboptimal protein 
sources [115] given the beneficial properties outlined above. Furthermore, FPH may also have 
applications in frail, prefrail, or under/malnourished older individuals [116]. The activation of MPS 
is driven to a substantial extent by the rapid postprandial increase in plasma leucine [93,94], and this 
effect is augmented by the provision of all EAAs, particularly following resistance exercise [117,118]. 
In skeletal muscle, mTORC1 is activated by leucine, and it positively promotes protein synthesis by 
phosphorylating two downstream effectors: p70S6K and 4E-BP1 [119–121]. After adjusting for 
participants’ body weight, the Nile tilapia-derived FPH utilised by Cordeiro et al. [68] contained less 
EAAs (approximately 24%) and leucine (approximately 31%) than WPH but nevertheless induced 
comparable postprandial aminoacidaemia. Although increased rates of MPS may seem to intertwine 
with translational signalling responses, the activation of mTORC1-associated substrates may persist 
long after MPS rates have normalised [122]. Therefore, future studies in older persons should 
integrate measures of protein synthesis to complement anabolic signalling targets in skeletal muscle. 
To our knowledge, no study has yet investigated the effects of FPH on anabolic signalling and MPS 
using in vitro, animal, or human models. 
Lastly, future studies should seek to compare FPH formulations with ‘established’ bioactive 
sources, such as WPH, as well as non-bioactive nitrogen-matched controls [123], to more thoroughly 
comprehend the true effect of hydrolysed fish protein supplementation on outcomes related to 
muscle health and function. The reviewed studies explored the effects of FPH on various aspects of 
human physiology and its regulation, yet often these investigations used protein-free placebos (i.e., 
cellulose, sucralose, maltodextrin) or did not control for nitrogen content between conditions. Hence, 
future studies would benefit from more robust control of these variables to confidently reveal the 
utility of FPH supplementation for human ageing health. 
5. Conclusions 
At present, there is limited work on the in vivo bioactivity of FPH formulations in humans, 
despite promising research in animal models. There is also a paucity of literature concerning the 
impact of FPH on general health and skeletal muscle anabolism in older adults. Although fish-
derived protein formulations appear to hold promise for promoting gut health, supporting body 
weight and fat mass losses, and driving post-exercise aminoacidaemia, these findings need to be 
corroborated in older populations. Further, comparisons of FPH with ‘established’ protein sources 
and/or non-bioactive protein controls would more cogently unravel the benefits of FPH. The potential 
applications of FPH as an alternative to whey-based formulations for older adults—particularly given 
the favourable subjective appetite ratings and regulatory hormone data—warrant further 
investigation. Future work should strive to understand the impact of fish-derived protein 
formulations on MPS and anabolic signalling responses, alone or in conjunction with resistance 
exercise. 
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